Allurion shares surge 13.27% intraday after announcing 23% weight loss and 14% lean mass gain in tirzepatide-combined study.

Allurion Technologies Inc. surged 13.27% intraday after announcing initial clinical results showing a 23% average total body weight loss and a 14% increase in lean body mass over 12 months when combining its Smart Capsule program with low-dose tirzepatide therapy. The study, involving 76 patients, highlighted improved adherence to tirzepatide (with no early discontinuations) and demonstrated a novel approach to addressing muscle loss and adherence challenges commonly associated with GLP-1 medications. The results, presented as a potential new standard for metabolically healthy weight loss, emphasized the company’s AI-powered virtual care suite’s role in monitoring and maintaining patient outcomes. This breakthrough underscores Allurion’s strategic pivot to combination therapies, aligning with growing demand for effective, long-term obesity management solutions.